Figure 1



A
L-IR 31min
R-nephrectomy
Fibrosis, kidney injury
Uninjured
Vehicle I/R-AKI
PYR 500
PYR 1000
-3
0
8
28 Days
Drug Treatment
B
C
D
E
F
Uninjured
Vehicle
PYR 500
PYR 1000

Figure 2.



A
B
Kim1 mRNA (fold change)
NGAL mRNA (fold change)
Uninjured
Vehicle I/R-AKI
PYR 500
PYR 1000
*
**
#

Figure 3



A
L-IR 31min
R-nephrectomy
Fibrosis, kidney injury
Uninjured
Vehicle I/R-AKI
PYR 1000 day1 after I/R-AKI
-3
0
1
8
28 Days
Drug Treatment
B
C
D
E
F
Uninjured
Vehicle
PYR 1000

Figure 4.



A
Kim1 mRNA (fold change)
1.8
1.6
1.4
1.2
1
0.8
0.6
0.4
0.2
0
*
B
NGAL mRNA (fold change)
40
35
30
25
20
15
10
5
0
**
*
Uninjured
Vehicle I/R-AKI
PYR 1000 day 1 after I/R-AKI

Figure 5




A
L-IR
31min
Injury evaluation
-3
0
3 Days
Drug Treatment
B
Uninjured
Vehicle I/R-AKI
PYR 500
PYR 1000
Kim1 mRNA (fold change)
C
NGAL mRNA (fold change)
D
Injury score (fold change)
E
Vehicle
PYR 500
PYR 1000
F
isoFlistoP, ng/g

Figure 6


A
B
PYR plasma concentrations, µg/mL, day3
PYR plasma concentration, µg/mL, day 28
Vehicle I/R-AKI
PYR 500
PYR 1000
*
**
0
1
2
3
4
5
6
8
10
12
14